Spectrum said the FDA had accepted its application for Rolontis, which had shown non-inferiority to Amgen's Neulasta in Phase III testing. However, oncologists expressed mixed opinions about the drug.
Poziotinib did not show an improved response rate among previously treated non-small cell lung cancer patients with a specific genetic mutation, but additional cohorts in the Phase II study are ongoing.
See how Quantum Health is providing the steps to help their members tackle the cost of specialty medications and other drugs.
CEO Joe Turgeon said in an interview that the company aims to focus more on developing drugs for larger, broader and more lucrative oncology markets.